Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Clinical and Experimental Immunology|June 1, 1979
Pulmonary function changes in normal rats induced by antibody against rat IgEF B Casey, B E Abboa-OffeiThe Journal of Pharmacology and Experimental Therapeutics|June 1, 1980
Antiallergic properties of SQ 13,847, an orally effective agent. I. Activity in vivoF B Casey, B E Abboa-Offei, J MarrettaJournal of Cardiovascular Pharmacology|September 1, 1996
Renal and depressor activity of C-natriuretic peptide in conscious monkeys: effects of enzyme inhibitorsA A Seymour, P D Mathers, B E Abboa-Offei, et al.The Journal of Pharmacology and Experimental Therapeutics|July 1, 1992
Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and ratsA A Seymour, M M Asaad, B E Abboa-Offei, et al.The Journal of Pharmacology and Experimental Therapeutics|February 1, 1996
Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitorsA A Seymour, M M Asaad, B E Abboa-Offei, et al.Journal of Cardiovascular Pharmacology|November 1, 1996
In vivo pharmacology of dual neutral endopeptidase/angiotensin-converting enzyme inhibitorsA A Seymour, M M Asaad, B E Abboa-Offei, et al.Clinical and Experimental Pharmacology & Physiology|January 1, 1995
Potentiation of natriuretic peptides by neutral endopeptidase inhibitorsA A Seymour, B E Abboa-Offei, P L Smith, et al.Journal of Cardiovascular Pharmacology|November 1, 1996
Renal and depressor activities of inhibitors of neutral endopeptidase and angiotensin converting enzyme in monkeys infused with angiotensin IIA A Seymour, M M Asaad, B E Abboa-Offei, et al.Journal of Medicinal Chemistry|May 23, 1997
Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidaseJ A Robl, C Q Sun, J Stevenson, et al.Bioorganic & Medicinal Chemistry Letters|May 30, 2007
Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformationsW N Washburn, T W Harper, G Wu, et al.Pageof 2